Antibodies
6 December 2010
Alexion Reports Results from First Clinical Trial of Novel Anti-Cancer Antibody Samalizumab at ASH Annual Meeting6 December 2010
ImmunoGen, Inc. Announces Presentation of Positive Initial Clinical Data for IMGN901 Used in a Combination Regimen for Multiple Myeloma6 December 2010
Single Dose ZEVALIN in First-Ever Phase 2 Monotherapy Trial for Non-Hodgkin’s Lymphoma Shows Significant and Durable Clinical Responses6 December 2010
New Phase II data from investigational compound GA101 presented today at the American Society of Hematology2 December 2010
MorphoSys and Xencor Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia1 December 2010
Peregrine Announces Initiation of Phase I/II Investigator-Sponsored Trial in Liver Cancer30 November 2010
ImmunoGen, Inc. Announces Initiation of Randomized Clinical Trial Evaluating IMGN901 for First-Line Treatment of Small-Cell Lung Cancer29 November 2010
Thallion and LFB Initiate Phase II SHIGATEC Trial24 November 2010
Innate Pharma Initiation of a Phase II Clinical Trial with Anti-KIR Monoclonal Antibody IPH 2101 in Smoldering Myeloma Patients22 November 2010
f-star and Boehringer Ingelheim to Collaborate in Discovery and Development of Therapeutic Antibodies22 November 2010
Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye in Wet Age-related Macular Degeneration19 November 2010
FDA Approves Amgen’s XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors18 November 2010
Curis Presents CUDC-101 Phase I Clinical Data and CU-201 Preclinical Data at 22nd EORTC-NCI-AACR Symposium17 November 2010
Peregrine’s Bavituximab Demonstrates Broad Potential in Viral Hemorrhagic Fever Infection Models16 November 2010
Anthera Pharmaceuticals, Inc. (ANTH) Suspends Enrollment and Dosing in PEARL-SC Clinical Trial to Address Reports of Vial Problems16 November 2010
ALLOZYNE Announces Positive Proof of Concept Data for AZ17, a Bispecific Th17 Antagonist for Treatment of Autoimmune Diseases15 November 2010
BioWa Announces License of POTELLIGENT Technology to AgensysNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports